Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
Authors
Keywords
-
Journal
LANCET INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-09-14
DOI
10.1016/s1473-3099(21)00125-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
- (2021) Muhammed O Afolabi et al. LANCET INFECTIOUS DISEASES
- Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate
- (2020) Ramon Roozendaal et al. npj Vaccines
- Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
- (2020) Andrew J Pollard et al. LANCET INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania
- (2019) Zacchaeus Anywaine et al. JOURNAL OF INFECTIOUS DISEASES
- Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya
- (2019) Gaudensia Mutua et al. JOURNAL OF INFECTIOUS DISEASES
- Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults
- (2019) Scott A Halperin et al. JOURNAL OF INFECTIOUS DISEASES
- EBOVAC-Salone: Lessons learned from implementing an Ebola vaccine trial in an Ebola-affected country
- (2018) Thomas Mooney et al. Clinical Trials
- “We are the heroes because we are ready to die for this country”: Participants' decision-making and grounded ethics in an Ebola vaccine clinical trial
- (2018) Angus Fayia Tengbeh et al. SOCIAL SCIENCE & MEDICINE
- Prevention of Ebola virus disease through vaccination: where we are in 2018
- (2018) Yves Lévy et al. LANCET
- Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankara–Vectored Ebola Vaccines at 1 Year
- (2017) Rebecca L. Winslow et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
- (2017) Ana Maria Henao-Restrepo et al. LANCET
- Considerations for use of Ebola vaccine during an emergency response
- (2017) Jenny A. Walldorf et al. VACCINE
- Protected to death: systematic exclusion of pregnant women from Ebola virus disease trials
- (2017) Melba F. Gomes et al. Reproductive Health
- Power, fairness and trust: understanding and engaging with vaccine trial participants and communities in the setting up the EBOVAC-Salone vaccine trial in Sierra Leone
- (2016) Luisa Enria et al. BMC PUBLIC HEALTH
- Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines
- (2016) Iain D. Milligan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More